Reported about 10 hours ago
Novo Nordisk's stock experienced an over 8% rise after the announcement of favorable Phase I clinical trial results for its new weight-loss medication, amycretin, which achieved up to 22% weight loss in participants. This drug aims to compete in the obesity market by mimicking hormones that suppress hunger. Despite previous setbacks with a comparable oral formulation, the encouraging results from the subcutaneous trials have sparked optimism for further successful trials in the future.
Source: YAHOO